José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
Use of an oral, delayed-release formulation of the ulcerative colitis treatment candidate PL-8177 led to targeted delivery to the lower gastrointestinal ... Read more
A positive test for the proteinase 3-anti-neutrophil cytoplasmic antibodies (PR3-ANCA) may differentiate ulcerative colitis (UC) from Crohn’s disease (CD) in children and adolescents ... Read more
Two global Phase 3 trials are evaluating upadacitinib as a potential treatment for adults with moderately to severely active Crohn’s disease ... Read more
Protagonist Therapeutics has begun dosing patients in a Phase 1 clinical trial of an oral ulcerative colitis (UC) treatment candidate known as ... Read more
The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease ... Read more
Olorinab, an investigational compound being developed by Arena Pharmaceuticals, significantly reduced chronic abdominal pain in patients with Crohn’s disease, according to topline ... Read more
About two-thirds of inflammatory bowel disease (IBD) specialists worldwide support continuing IBD medications when traveling to tuberculosis (TB)-endemic areas, while about ... Read more
Treating inflammatory bowel disease (IBD) with fecal microbiota transplant (FMT) shows potential, but longer clinical trials and more information on the best ... Read more
Eating vegetables and whole grains reduces the risk of Crohn’s disease, while eating more fruit and beans/legumes lowers the risk of ulcerative ... Read more
